Skip to main content

Institutional intelligence for Ishita Drugs & Industries Ltd

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Tracked super investors holding ≥1%

Ownership breakdown

Estimated from named holders at or above 1% in the latest filing (Jun 2026). Official category totals not yet parsed. Sums to 90.05%.

  • Promoters47.19%
  • Retail & others (est.)42.86%
  • Super Investors 2.15%(subset)
  • 1% Club 7.80%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive.

Holder details (≥1% disclosed names)

Promoters

Promoter & promoter group

9 named
HolderStakeSharesValue (₹ Cr)
9.94%2,97,300₹2.2 Cr
8.39%2,50,796₹1.9 Cr
7.76%2,31,969₹1.7 Cr
4.68%1,40,000₹1.0 Cr
4.41%1,31,809₹98.0 L
4.35%1,30,000₹97.0 L
3.48%1,04,150₹78.0 L
2.84%85,000₹63.0 L
1.34%40,000₹30.0 L

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

7.80%5 named
HolderStakeSharesValue (₹ Cr)
3.34%1,00,001₹75.0 L
1.36%40,684₹30.0 L
1.10%32,920₹25.0 L
1.00%29,940₹22.0 L
1.00%29,998₹22.0 L

Super Investors

Curated tracked investor profiles

2.15%1 named
HolderStakeSharesValue (₹ Cr)
Tracked as Mahendra Girdharilal2.15%64,182₹48.0 L

DII (other)

Insurance, banks, AIF, other domestic institutions

No names

No named holders ≥1% in this bucket.

FII / FPI

Foreign portfolio investors

No names

No named holders ≥1% in this bucket.

Mutual Funds

Domestic mutual funds & UTI

No names

No named holders ≥1% in this bucket.

Retail & others

Holders below 1% disclosure threshold and public non-institutions

SEBI requires naming only shareholders with ≥1% stake. The remaining includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.